SBRT 7Gy✖️5 QD

DRUG2 trials

Sponsors

Hubei Cancer Hospital, Eastern Hepatobiliary Surgery Hospital

Conditions

Biliary Tract Cancer (BTC)NSCLC

Phase 1

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

CompletedNCT05021328

Hubei Cancer HospitalNSCLC

Start: 2021-10-01End: 2025-02-05Updated: 2025-02-07

Phase 2

Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer

Not yet recruitingNCT07638501

Eastern Hepatobiliary Surgery HospitalBiliary Tract Cancer (BTC)

Start: 2026-06-15End: 2029-06-15Target: 123Updated: 2026-06-10

Related Papers

Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.

Journal of Clinical Oncology2023-06-012 citations